Say, L, Chou, D, Gemmill, A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health, 2014;2(6):e323–33.Google Scholar

Lindheimer, MD, Taler, SJ, Cunningham, FG. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich), 2009;11(4):214–25.CrossRefGoogle ScholarPubMed

Lo, JO, Mission, JF, Caughey, AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol, 2013;25(2):124–32.Google Scholar

Foo, L, Bewley, S, Rudd, A. Maternal death from stroke: a thirty year national retrospective review. Eur J Obstet Gynecol Reprod Biol, 2013;171(2):266–70.CrossRefGoogle ScholarPubMed

National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol, 2000;183(1):S1–S22.CrossRefGoogle Scholar

NICE. National Institute for Health and Clinical Excellence: (CG107) Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. 2011: London.Google Scholar

Paruk, F, Moodley, J. Untoward effects of rapid-acting antihypertensive agents. Best Pract Res Clin Obstet Gynaecol, 2001;15(4):491–506.CrossRefGoogle ScholarPubMed

Redman, C. Hypertension, in Medical disorders in obstetric practice, Swiet, M.de, Editor. 2002, Blackwell Publishing Company.159–197.Google Scholar

Tranquilli, AL, Dekker, G, Magee, L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens, 2014;4(2):97–104.Google Scholar

Sibai, BM, Ewel, M, Levine, RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol, 1997;177(5):1003–10.CrossRefGoogle ScholarPubMed

Ghosh, G, Grewal, J, Männistö, T, et al. Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women. Ethn Dis, 2014;24(3):283–9.Google ScholarPubMed

Chaturvedi, N, McKeigue, PM, Marmot, MG. Resting and ambulatory blood pressure differences in Afro-Caribbeans and Europeans. Hypertension, 1993;22(1):90–6.CrossRefGoogle ScholarPubMed

Valensise, H, Novelli, GP, Vasapollo, B. Pre-eclampsia: One name, two conditions – the case for early and late disease being different. Fetal Matern Med Rev, 2014;24:32–7.Google Scholar

Ferrazzi E, ST, Aupont, JE. The evidence for late-onset pre-eclampsia as a maternogenic disease of pregnancy. Fetal Matern Med Rev, 2013; 24(1):18–31.Google Scholar

Huppertz, B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension, 2008; 51(4):970–5.CrossRefGoogle ScholarPubMed

Sibai, B, Dekker, G, Kupferminc, M. Pre-eclampsia. Lancet, 2005;365(9461):785–99.Google Scholar

Levine, RJ, Lam, C, Qian, C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med, 2006;355(10):992–1005.Google Scholar

Levine, RJ, Maynard, SE, Qian, C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 2004;350(7):672–83.Google Scholar

Xiong, X, Demianczuk, NN, Saunders, LD, Wang, FL, Fraser, WD Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol, 2002;155(3):203–9.Google Scholar

Ananth, CV, Peltier, MR, Kinzler, WL, Smulian, JC, Vintzileos, AM. Chronic hypertension and risk of placental abruption: is the association modified by ischemic placental disease? Am J Obstet Gynecol, 2007;197(3):273 e1–7.CrossRefGoogle ScholarPubMed

Haelterman, E, Bréart, G, Paris-Llado, J, Dramaix, M, Tchobroutsky, C. Effect of uncomplicated chronic hypertension on the risk of small-for-gestational age birth. Am J Epidemiol, 1997;145(8):689–95.CrossRefGoogle ScholarPubMed

Walfisch, A, Al-maawali, A, Moretti, ME, Nickel, C, Koren, G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol, 2011;31(6):465–72.Google Scholar

Piper, JM, Ray, WA, Rosa, FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol, 1992;80(3 Pt 1):429–32.Google ScholarPubMed

Rosa, FW, Bosco, LA, Graham, CF, Milstien, JB, Dreis, M, Creamer, J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol, 1989;74(3 Pt 1):371–4.Google Scholar

Kincaid-Smith, P, Bullen, M, Mills, J. Prolonged use of methyldopa in severe hypertension in pregnancy. Br Med J, 1966;1(5482):274–6.Google Scholar

Ananth, CV, Savitz, DA, Bowes, WA, Luther, ER. Influence of hypertensive disorders and cigarette smoking on placental abruption and uterine bleeding during pregnancy. Br J Obstet Gynaecol, 1997;104(5):572–8.Google Scholar

Romero-Arauz, JF, Ortiz-Diaz, CB, Leaños-miranda, A, Martinez-Rodriguez, OA. Progression of gestational hypertension to preeclampsia. Ginecol Obstet Mex, 2014;82(4):229–35.Google Scholar

Anumba, DO, Lincoln, K, Robson, SC. Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension. Hypertens Pregnancy, 2010;29(2):163–79.Google Scholar

Villar, J, Carroli, G, Wojdyla, D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol, 2006;194(4):921–31.Google Scholar

Buchbinder, A, Sibai, BM, Caritis, S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol, 2002;186(1):66–71.Google Scholar

Steer, PJ, Little, MP, Kold-Jensen, T, Chapple, J, Elliott, P. Maternal blood pressure in pregnancy, birth weight, and perinatal mortality in first births: prospective study. BMJ, 2004;329(7478):1312.Google Scholar

Al Khaja, KAJ, Sequeira, P, Alkhaja, AK, Damanhori, AH. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens, 2014;32(3):454–63.Google Scholar

Mutch, LM, Moar, VA, Ounsted, MK, Redman, CW. Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life. Early Hum Dev, 1977;1(1):59–67.Google Scholar

Cockburn, J, Moar, VA, Ounsted, M, Redman, CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet, 1982;1(8273):647–9.Google Scholar

el-Qarmalawi, AM, Morsy, AH, al-Fadly, A, Obeid, A, Hashem, M. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet, 1995. 49(2):125–30.Google Scholar

Huisjes, HJ, Hadders-Algra, M, Touwen, BC. Is clonidine a behavioural teratogen in the human? Early Hum Dev, 1986. 14(1):43–8.Google Scholar

Chobanian, AV, Bakris, GL, Black, HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003;289(19):2560–72.CrossRefGoogle ScholarPubMed

Butters, L, Kennedy, S, Rubin, PC. Atenolol in essential hypertension during pregnancy. BMJ, 1990;301(6752):587–9.Google Scholar

Lip, GY, Beevers, M, Churchill, D, Shaffer, LM, Beevers, DG. Effect of atenolol on birth weight. Am J Cardiol, 1997;79(10):1436–8.Google Scholar

Yakoob, MY, Bateman, BT, Ho, E, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension, 2013;62(2):375–81.Google Scholar

Sorensen, HT, Czeizel, AE, Rockenbauer, M, Steffensen, FH, Olsen, J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand, 2001;80(5):397–401.Google Scholar

Danielsson, BR, Reiland, S, Rundgvist, E, Danielson, M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology, 1989;40(4):351–8.Google Scholar

Scott, WJ, Jr., Resnick, E, Hummler, H, Clozel, JP, Bürgin, H. Cardiovascular alterations in rat fetuses exposed to calcium channel blockers. Reprod Toxicol, 1997;11(2–3):207–14.CrossRefGoogle ScholarPubMed

Brown, MA, Buddle, ML, Farrell, T, Davis, GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol, 2002;187(4):1046–50.Google Scholar

Impey, L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol, 1993;100(10):959–61.Google Scholar

Papatsonis, DN, Lok, CA, Bos, JM, Geijn, HP, Dekker, GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol, 2001;97(2):122–40.Google Scholar

Ben-Ami, M, Giladi, Y, Shalev, E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol, 1994;101(3):262–3.Google Scholar

Ales, K. Magnesium plus nifedipine. Am J Obstet Gynecol, 1990;162(1):288.Google Scholar

Magee, LA, Miremadi, S, Li, J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol, 2005;193(1):153–63.Google Scholar

Vasilakis-Scaramozza, C, Aschengrau, A, Cabral, HJ, Jick, SS. Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy, 2013;33(5):476–82.Google Scholar

Cooper, WO, Hernandez-Diaz, S, Arbogast, PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med, 2006;354(23):2443–51.CrossRefGoogle ScholarPubMed

Quan, A, Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev, 2006;82(1):23–8.Google Scholar

Alwan, S, Polifka, JE, Friedman, JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol, 2005;73(2):123–30.CrossRefGoogle ScholarPubMed

Groves, TD, Corenblum, B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol, 1995;172(5):1655–6.Google Scholar

Spinnato, JA, Sibai, BM, Anderson, GD. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. South Med J, 1986;79(5):559–62.Google Scholar

Paterson-Brown, S, Robson, SC, Redfern, N, Walkinshaw, SA, de Swiet, M. Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia. Br J Obstet Gynaecol, 1994;101(5):409–13.Google Scholar

Davis, RL, Eastman, D, McPhillips, H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf, 2011;20(2):138–45.CrossRefGoogle ScholarPubMed

Olsen, KS, Beier-Holgersen, R. Hemodynamic collapse following labetalol administration in preeclampsia. Acta Obstet Gynecol Scand, 1992;71(2):151–2.Google Scholar

Magee, LA, Cham, C, Waterman, EJ, Ohlsson, A, von Dadelszen, P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ, 2003;327(7421):955–60.Google Scholar

Vigil-De Gracia, P, Lasso, M, Ruiz, E, Vega-Malek, JC, de Mena, FT, Lopez, JC. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol, 2006;128(1–2):157–62.Google Scholar

Duley, L, Henderson-Smart, DJ, Meher, S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev, 2006;3:CD001449.Google Scholar

Firoz, T, Magee, LA, MacDonnell, K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG, 2014;121(10):1210–8; discussion 1220.Google Scholar

Rumbold, AR, Crowther, CA, Haslam, RR, Dekker, GA, Robinson, JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med, 2006;354(17):1796–806.Google Scholar

Poston, L, Briley, AL, Seed, PT, Kelly, FJ, Shennan, AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomized placebo-controlled trial. Lancet, 2006;367(9517):1145–54.Google Scholar

Conde-Agudelo, A, Romero, R, Kusanovic, JP, Hassan, SS. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology, 2011;204(6):503.CrossRefGoogle Scholar

Basaran, A, Basaran, M, Topatan, B. Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis. Obstet Gynecol Surv, 2010;65(10):653–67.Google Scholar

Romero, R, Garite, TJ. Unexpected results of an important trial of vitamins C and E administration to prevent preeclampsia. Am J Obstet Gynecol, 2006;194(5):1213–4.Google Scholar

Banerjee, S, Chambers, AE, Campbell, S. Is vitamin E a safe prophylaxis for preeclampsia? Am J Obstet Gynecol, 2006;194(5):1228–33.CrossRefGoogle ScholarPubMed

Ramsay, B, De Belder, A, Campbell, S, Moncada, S, Martin, JF. A nitric oxide donor improves uterine artery diastolic blood flow in normal early pregnancy and in women at high risk of pre-eclampsia. Eur J Clin Invest, 1994;24(1):76–8.Google Scholar

Manzur-Verástegui, S, Mandeville, PB, Gordillo-Moscoso, A, Hernández-Sierra, JF, Rodríguez-Martínez, M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol, 2008;35(5–6):580–5.CrossRefGoogle ScholarPubMed

Cetin, A, Yurtcu, N, Guvenal, T, Imir, AG, Duran, B, Cetin, M. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hypertens Pregnancy, 2004;23(1):37–46.Google Scholar

Lees, C, Valensise, H, Black, R, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol, 1998;12(5):334–8.Google Scholar

Schleussner, E, Lehmann, T, Kähler, C, Schneider, U, Schlembach, D, Groten, T. Impact of the nitric oxide-donor pentaerythrityl-tetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, double-blinded trial. J Perinat Med, 2014;42(4):507–14.Google Scholar

de Belder, A, Lees, C, Martin, J, Moncada, S, Campbell, S. Treatment of HELLP syndrome with nitric oxide donor. Lancet, 1995;345(8942):124–5.Google Scholar

Lees, C, Langford, E, Brown, AS, et al. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol, 1996;88(1):14–9.Google Scholar

Khalil, A, Akolekar, R, Syngelaki, A, Elkhouli, M, Nicolaides, KH. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol, 2012;40(1):28–34.Google Scholar

Everett, TR, Wilkinson, IB, Mahendru, AA, et al. S-Nitrosoglutathione improves haemodynamics in early-onset pre-eclampsia. Br J Clin Pharmacol, 2014;78(3):660–9.Google Scholar

Hernandez-Diaz, S, Toh, S, Cnattingius, S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ, 2009;338:b2255.Google Scholar

Basso, O, Christensen, K, Olsen, J. Higher risk of pre-eclampsia after change of partner. An effect of longer interpregnancy intervals? Epidemiology, 2001;12(6):624–9.Google Scholar

Hargood, JL, Brown, MA. Pregnancy-induced hypertension: recurrence rate in second pregnancies. Med J Aust, 1991;154(6):376–7.Google Scholar

Trogstad, L, Skrondal, A, Stoltenberg, C, Magnus, P, Nesheim, BI, Eskild, A. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A, 2004;126A(1):41–5.Google Scholar

Facchinetti, F, Longo, M, Piccinini, F, Neri, I, Volpe, A. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Investig, 1999;6(4):202–7.Google Scholar

Cindrova-Davies, T. The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front Pharmacol, 2014;5:119.Google Scholar

Fox, KA, Longo, M, Tamayo, E, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol, 2011;205(4):366 e1–5.Google Scholar

Kumasawa, K, Ikawa, M, Kidoya, H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A, 2011;108(4):1451–5.Google Scholar

Ahmed, A, Singh, J, Khan, Y, Seshan, SV, Girardi, G. A new mouse model to explore therapies for preeclampsia. PLoS One, 2010;5(10):e13663.Google Scholar

Redecha, P, van Rooijen, N, Torry, D, Girardi, G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood, 2009;113(17):4101–9.Google Scholar

NICE. National Institute for Health & Clinical Excellence: (CG37) Routine post-natal care of women and their babies. 2006.Google Scholar

Cantwell, R, Clutton-Brock, T, Cooper, G, et al. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG, 2011;118 Suppl 1:1–203.Google Scholar

Podymow, T, August, P, Umans, JG. Antihypertensive therapy in pregnancy. Semin Nephrol, 2004;24(6):616–25.Google Scholar

Redman, CWG, Kelly, JG, Cooper, WD. The excretion of enalapril and enalaprilat in human breast-milk. European Journal of Clinical Pharmacology, 1990;38(1):99.Google Scholar

Lunell, NO, Kulas, J, Rane, A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol, 1985;28(5):597–9.Google Scholar

Bramham, K, Nelson-Piercy, C, Brown, MJ, Chappell, LC. Postpartum management of hypertension. BMJ, 2013;346:f894.CrossRefGoogle ScholarPubMed

Duley, L, Henderson-Smart, DJ, Meher, S, King, JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2007; 2:CD004659.Google Scholar

Awtry, EH, Loscalzo, J. Aspirin. Circulation 2000;101:1206–18.Google Scholar

Patrono, C, Collar, B, Dalen, J et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;114:470S–488S.Google Scholar

Farivar, RS, Brecher, P. Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts. J Biol Chem 1996;271:31585–92.Google Scholar

Bradlow, BA, Chetty, N. Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res 1982;27:99–110.Google Scholar

Patrignani, P, Filabozzi, P, Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366 –72.CrossRefGoogle ScholarPubMed

Duley, L, Meher, S, Hunter, K, Askie, L. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2018 (in press).Google Scholar

Roberts, JM, Hubel, CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30 Suppl A:S32–7.Google Scholar

Young, BC, Levine, RJ, Karumanchi, SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010;5:173–92.Google Scholar

Pijnenborg, R, Bland, JM, Robertson, WB, et al. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983;4: 397–413.Google Scholar

Viinikka, L, Hartikainen-Sorri, AL, Lumme, R, et al. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin thromboxane balance in mother and newborn. Br J Obstet Gynaecol 1993;100: 809–15.Google Scholar

Schiff, E, Peleg, E, Goldenberg, M, et al. The use of aspirin to prevent pregnancy induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. New Engl J Med 1989;321: 351–6.Google Scholar

Benigni, A, Gregorini, G, Frusca, T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy induced hypertension. New Engl J Med 1989;321:357–62.Google Scholar

Johnson, RD, Polakoski, K, Everson, WV, et al. Aspirin induces increased expression of both prostaglandin H synthase-1 and prostaglandin H synthase-2 in cultured human placental trophoblast. Am J Obstet Gynecol 1997;177(1):78–85.Google Scholar

Han, CS, Mulla, MJ, Brosens, JJ, et al. Aspirin and heparin effect on basal and antiphos-pholipid antibody modulation of trophoblast function. Obstet Gynecol 2011;118(5):1021–8.Google Scholar

Bose, P, Black, S, Kadyrov, M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005;192(1):23–30.Google Scholar

Owen, J, Maher, JE, Hauth, JC, et al. The effect of low-dose aspirin on umbilical artery Doppler measurements. Am J Obstet Gynecol 1993;169(4):907–11.Google Scholar

Bar, J, Hod, M, Pardo, J, et al. Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound Obstet Gynecol 1997;9(4):262–5.Google Scholar

Grab, D, Paulus, WE, Erdmann, M, et al. Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol. 2000;15(1):19–27.Google Scholar

Haapsamo, M, Martikainen, H, Räsänen, J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol 2008;32(5):687–93Google Scholar

Cusick, W, Salafia, CM, Ernst, L, et al. Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. Am J Reprod Immunol 1995;34(3):141–7.Google Scholar

Tarim, E, Bal, N, Kilicdag, E, et al. Effects of aspirin on placenta and perinatal outcomes in patients with poor obstetric history. Arch Gynecol Obstet 2006;274:209–14.Google Scholar

Askie, LM, Duley, L, Henderson-Smart, DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–8.Google Scholar

Baron, JA, Senn, S, Voelker, M, et al. Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Drugs R D 2013;13:9–16.Google Scholar

Kozer, E, Nifkar, S, Costei, A, et al. Aspirin consumption during the first trimester of pregnancy and congenital abnormalities: a meta-analysis. Am J Obstet Gynaecol 2002;187:1623–30.Google Scholar

Duckitt, K, Harrington, D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330(7491):565.Google Scholar

Akolekar, R, Syngelaki, A, Poon, L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagnosis and Therapy 2013;33(1):8–15.Google Scholar

Rolnik, DL, Wright, D, Poon, LC, O'Gorman, N, Syngelaki, A, de Paco, Matallana C, Akolekar, R, Cicero, S, Janga, D, Singh, M, Molina, FS, Persico, N, Jani, JC, Plasencia, W, Papaioannou, G, Tenenbaum-Gavish, K, Meiri, H, Gizurarson, S, Maclagan, K, Nicolaides, KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017 Aug 17;377(7):613–622.Google Scholar

Roberge, S, Nicolaides, K, Demers, S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013;41(5):491–9.Google Scholar

Meher, S, Duley, L, Hunter, K et al. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017;216(2):121–8.Google Scholar

Neubauer, H, Kaiser, AF, Endres, HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance–the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011;9:3.Google Scholar

Rey, E, Rivard, G-E. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet, Gynecol Reprode Biol 2011;157(1):38–42.Google Scholar

Wojtowicz, A, Undas, A, Huras, H, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett 2011;32(3):334–9.Google Scholar

Charnock-Jones, DS, Kaufmann, P, Mayhew, TM. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 2004;25:103–13.Google Scholar

Konje, JC, Howarth, ES, Kaufmann, P, Taylor, DJ. Longitudinal quantification of uterine artery blood volume flow changes during gestation in pregnancies complicated by intrauterine growth restriction. BJOG. 2003;110(3):301–5.CrossRefGoogle ScholarPubMed

Ferrara, N, Gerber, HP, Le Couter, J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.Google Scholar

Holmes, DI, Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6:209.Google Scholar

Zachary, I. Neuropilins: role in signalling, angiogenesis and disease. Chem Immunol Allergy. 2014;99: 37–70.Google Scholar

Binder, NK, Evans, J, Gardner, DK, Salamonsen, LA, Hannan, NJ. Endometrial signals improve embryo outcome: functional role of vascular endothelial growth factor isoforms on embryo development and implantation in mice. Hum Reprod. 2014;29(10):2278–86.Google Scholar

Carmeliet, P, Ferreira, V, Breier, G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435–9.Google Scholar

Kaufmann, P, Mayhew, TM, Charnock-Jones, DS. Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta. 2004;25(2–3):114–26.CrossRefGoogle ScholarPubMed

Andraweera, PH, Dekker, GA, Roberts, CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update. 2012;18(4):436–57.Google Scholar

Romero, R, Nien, JK, Espinoza, J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal Neonatal Med. 2008;21:9–23.Google Scholar

Jain, RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–22.CrossRefGoogle ScholarPubMed

Martin, DF, Maguire, MG. Treatment choice for diabetic macular edema. N Engl J Med. 2015 Mar 26;372(13):1260–1.Google Scholar

Baumgartner, I, Pieczek, A, Manor, O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97(12):1114–23.Google Scholar

Sanada, F, Taniyama, Y, Kanbara, Y, et al. Gene therapy in peripheral artery disease. Expert Opin Biol Ther 2015;15(3):381–90.Google Scholar

Banai, S, Shweiki, D, Pinson, A, et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994;28:1176–9.Google Scholar

Henry, TD, Annex, BH, McKendall, GR, et al. VIVA Investigators The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359–65Google Scholar

Rubanyi, GM. Identifying and overcoming obstacles in angiogenic gene therapy for myocardial ischemia. J Cardiovasc Pharmacol 2014;64 (2):109–19.CrossRefGoogle ScholarPubMed

Spencer, RN, Carr, DJ, David, AL. Treatment of poor placentation and the prevention of associated adverse outcomes – what does the future hold? Prenat Diagn, 2014;34:677–84.Google Scholar

Baschat, AA, Cosmi, E, Bilardo, CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol. 2007;109(2 Pt 1):253–61.CrossRefGoogle ScholarPubMed

Spencer, R, Carr, DJ, David, A. Gene therapy for obstetric conditions. Fetal Matern Med Rev, 2015;25(3–4):147–77.Google Scholar

David, AL, Torondel, B, Zachary, I, et al. Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther 2008;15:1344–50.Google Scholar

Mehta, V, Abi-Nader, KN, Shangaris, P, et al. Local over-expression of VEGF-D^ΔNΔC in the uterine arteries of pregnant sheep results in long-term changes in uterine artery contractility and angiogenesis. PLoS One, 2014;99.(6):e100021Google Scholar

Mehta, V, Abi-Nader, K, Peebles, D, et al. Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A(165) in the uterine arteries of pregnant sheep. Gene Ther 2011;September: 86–96.Google ScholarPubMed

Wallace, JM, Luther, JS, Milne, JS, et al. Nutritional modulation of adolescent pregnancy outcome – a review. Placenta. 2006; 27 Suppl A: S61–8.Google Scholar

Carr, DJ, Aitken, RP, Milne, JS, David, AL, Wallace, JM. Ultrasonographic assessment of growth and estimation of birthweight in late gestation fetal sheep. Ultrasound Med Biol. 2011; 37(10):1588–95.Google Scholar

Smith, GC, Smith, MF, McNay, MB, Fleming, JE. The relation between fetal abdominal circumference and birthweight: findings in 3512 pregnancies. BJOG. 1997; 104(2):186–90.Google Scholar

Carr, DJ, Wallace, JM, Aitken, RP, et al. Uteroplacental adenovirus vascular endothelial growth factor gene therapy increases fetal growth velocity in growth-restricted sheep pregnancies. Hum. Gene Ther 2014;25:375–84.Google Scholar

Carr, DJ, Wallace, JM, Aitken, R, et al. Peri- and postnatal effects of prenatal adenoviral VEGF gene therapy in growth-restricted sheep. Biol. Reprod 2016;9: 142.Google Scholar

Swanson, AM, Mehta, V, Ofir, K, et al. The use of ultrasound to assess fetal growth in a guinea pig model of fetal growth restriction. Lab. Anim. Apr 26. pii: 0023677216637506Google Scholar

Carter, AM. Animal models of human placentation–a review. Placenta. 2007;28 Suppl A:S41–7.Google Scholar

Swanson, A, Rossi, C, Ofir, K, et al. Maternal uterine artery gene therapy with Ad.VEGF-A165 increases weight at term in a guinea pig model of fetal growth restriction. Hum Gene Ther 2015;26:A14.Google Scholar

Feldman, LJ, Pastore, CJ, Aubailly, N., et al. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther 1997;4(3):189–98.Google Scholar

Pelage, JP, Dref, O, Le Mateo, J, et al. Life-threatening primary postpartum hemorrhage: treatment with emergency selective arterial embolization. Radiology 1998;208:359–62.Google Scholar

Angstmann, T, Gard, G, Harrington, T, Ward, E, Thomson, A, Giles, W. Surgical management of placenta accreta: a cohort series and suggested approach. Am J Obstet Gynecol 2010;202(1):38.e1–9.Google Scholar

Sheppard, MK, David, AL, Spencer, R, Ashcroft, R. Consortium, E, Ethics and ethical evaluation of a proposed clinical trial with maternal uterine artery vascular endothelial growth factor gene therapy to treat severe early onset fetal growth restriction in pregnant. Hum. Gene Ther 2014;25:A98.Google Scholar

Senger, DR, Asch, BB, Smith, BD, Perruzzi, CA, Dvorak, HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983 Apr 21;302(5910):714–5.Google Scholar

Poston, L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep 2006;58:69–74.Google Scholar

Roberts, JM, Hubel, CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30:32–7.Google Scholar

Savvidou, MD, Hingorani, AD, Tsikas, D, Frölich, JC, Vallance, P, Nicolaides, KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361:1511–7.CrossRefGoogle ScholarPubMed

López-Alarcón, M, Montalvo-Velarde, I, Vital-Reyes, VS, Hinojosa-Cruz, JC, Leaños-Miranda, A, Martínez-Basila, A. Serial determinations of asymmetric dimethylarginine and homocysteine during pregnancy to predict pre-eclampsia: a longitudinal study. BJOG 2015;122:1586–92.CrossRefGoogle ScholarPubMed

Koga, K, Osuga, Y, Yoshino, O, Hirota, Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348–51.Google Scholar

Krauss, T, Pauer, H-U, Augustin, HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004;23:101–11.Google Scholar

Romero, R, Nien, JK, Espinoza, J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23.Google Scholar

Venkatesha, S, Toporsian, M, Lam, C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–9.Google Scholar

Hood, JD, Meininger, CJ, Ziche, M, Granger, HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054–8.Google Scholar

Kroll, J, Waltenberger, J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998;252:743–6.Google Scholar

Ahmad, S, Hewett, PW, Wang, P, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res. 2006;99:715–22.Google Scholar

Maynard, SE. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.Google Scholar

Levine, RJ, Maynard, SE, Qian, C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83.Google Scholar

Inoue, N, Venema, RC, Sayegh, HS, Ohara, Y, Murphy, TJ, Harrison, DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta. Arterioscler Thromb Vascular Biol. 1995;15:1255–61.Google Scholar

Santibanez, JF, Letamendia, A, Perez-Barriocanal, F, et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 2007;210:456–68.Google Scholar

Sandrim, VC, Palei, ACT, Metzger, IF, Gomes, VA, Cavalli, RC, Tanus-Santos, JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008;52:402–7.Google Scholar

Chen, Z, Zhang, J, Stamler, JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USa 2002;99:8306–11.Google Scholar

Ramsay, B, de Belder, A, Campbell, S, Moncada, S, Martin, JF. A nitric oxide donor improves uterine artery diastolic blood flow in normal early pregnancy and in women at high risk of pre-eclampsia. Eur J Clin Invest 1994;24:76–8.Google Scholar

Grunewald, C, Kublickas, M, Carlström, K, Lunell, NO, Nisell, H. Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia. Obstet Gynecol. 1995;86:600–4.Google Scholar

Cetin, A, Yurtcu, N, Guvenal, T, Imir, AG, Duran, B, Cetin, M. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hypertens Pregnancy 2004;23:37–46.Google Scholar

Manzur-Verástegui, S, Mandeville, PB, Gordillo-Moscoso, A, Hernández-Sierra, JF, Rodríguez-Martínez, M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol 2008;35:580–5.Google Scholar

Lees, C, Valensise, H, Black, R, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 2002;12:334–8.Google Scholar

Picciolo, C, Roncaglia, N, Neri, I. Nitric oxide in the prevention of pre-eclampsia. Prenat Neonatal Med 2000;5:212–5.Google Scholar

Cacciatore, B, Halmesmäki, E, Kaaja, R, Teramo, K, Ylikorkala, O. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998;179:140–5.Google Scholar

Trapani, A, Gonçalves, LF, Pires, MM de S. Transdermal nitroglycerin in patients with severe pre-eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011;38:389–94.Google Scholar

Luzi, G, Caserta, G, Iammarino, G, Clerici, G, Di Renzo, GC. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor. Ultrasound Obstet Gynecol 1999;14:101–9.Google Scholar

Gori, T, Parker, JD. Nitrate Tolerance. A Unifying Hypothesis. Circulation 2002;106:2510–3.Google Scholar

Miller, MR, Megson, IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol. 2009;151:305–21.Google Scholar

Davis, DG, Brown, PM. Re: glyceryl trinitrate (GTN) patches are unsuitable in hypertensive pregnancy. Aust N Z J Obstet Gynaecol 2001;41:474.Google Scholar

Thaler, I, Amit, A, Kamil, D, Itskovitz-Eldor, J. The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension. Am J Hypertens. 1999;12:341–7.Google Scholar

Martínez-Abundis, E, González-Ortiz, M, Hernández-Salazar, F, Huerta-J-Lucas, MT. Sublingual isosorbide dinitrate in the acute control of hypertension in patients with severe preeclampsia. Gynecol Obstet Invest 2000;50:39–42.Google Scholar

Nakatsuka, M, Takata, M, Tada, K, et al. A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. J Ultrasound Med 2002;21:831–6.Google Scholar

Thaler, I, Amit, A, Jakobi, P, Itskovitz-Eldor, J. The effect of isosorbide dinitrate on uterine artery and umbilical artery flow velocity waveforms at mid-pregnancy. Obstet Gynecol. 1996;88:838–43.Google Scholar

Makino, Y, Izumi, H, Makino, I, Shirakawa, K. The effect of nitric oxide on uterine and umbilical artery flow velocity waveform in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73:139–43.Google Scholar

Groten, T, Lehmann, T, Fitzgerald, J, et al. Reduction of preeclampsia related complications with with the NO-donor penterythriltetranitrat (PETN) in risk pregnancies – a prospective randomized double-blind placebo pilot study. Pregnancy Hypertens. 2012; Jul;2(3):181.Google Scholar

Immink, RV, van den Born, B-JH, van Montfrans, GA, Kim, Y-S, Hollmann, MW, van Lieshout, JJ. Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 2008;52:236–40.Google Scholar

National Institute for Health and Care Excellence (2010) Hypertension in Pregnancy. CG107. London: National Institute for Health and Care Excellence.Google Scholar

Sayed, N, Kim, DD, Fioramonti, X, Iwahashi, T, Duran, WN, Beuve, A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008;103:606–14.Google Scholar

Bryan, NS, Rassaf, T, Maloney, RE, et al. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci USa 2004;101:4308–13.Google Scholar

de Belder, AJ, MacAllister, R, Radomski, MW, Moncada, S, Vallance, PJ. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994;28:691–4.Google Scholar

Ramsay, B, Radomski, M, de Belder, A, Martin, JF, Lopez-Jaramillo, P. Systemic effects of S-nitroso-glutathione in the human following intravenous infusion. Br J Clin Pharmacol 1995;40:101–2.Google Scholar

Langford, EJ, Brown, AS, Wainwright, RJ, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994;344:1458–60.Google Scholar

Langford, E, Wainwright, R, Martin, J. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 1996;16:51–55.Google Scholar

de Belder, A, Lees, C, Martin, J, Moncada, S, Campbell, S. Treatment of HELLP syndrome with nitric oxide donor. Lancet 1995;345:124–5.Google Scholar

Lees, C, Langford, E, Brown, AS, et al. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 1996;88:14–9.Google Scholar

Everett, TR, Wilkinson, IB, Mahendru, AA, et al. S-Nitrosoglutathione improves haemodynamics in early-onset pre-eclampsia. Br J Clin Pharmacol 2014;78:660–9.Google Scholar

Hausvater, A, Giannone, T, Sandoval, Y-HG, et al. The association between preeclampsia and arterial stiffness. J Hypertens. 2012;30:17–33.Google Scholar

Martínez-Ruiz, A, Lamas, S. Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc Res 2007;75:220–8.Google Scholar

Kaposzta, Z, Clifton, A, Molloy, J, Martin, JF, Markus, HS. S-nitrosoglutathione reduces asymptomatic embolization after carotid angioplasty. Circulation 2002;106:3057–62.Google Scholar

Zhou, A, Carrell, RW, Murphy, MP, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010;468:108–11.Google Scholar

Rani, N, Dhingra, R, Arya, DS, Kalaivani, M, Bhatla, N, Kumar, R. Role of oxidative stress markers and antioxidants in the placenta of preeclamptic patients. J Obstet Gynaecol Res 2010;36:1189–94.Google Scholar

Knapen, MF, Mulder, TP, Van Rooij, IA, Peters, WH, Steegers, EA. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998;92:1012–5.Google Scholar

Raijmakers, MT, Zusterzeel, PL, Steegers, EA, Hectors, MP, Demacker, PN, Peters, WH. Plasma thiol status in preeclampsia. Obstet Gynecol 2000;95:180–4.Google Scholar

Kaposzta, Z, Martin, JF, Markus, HS. Switching off embolization from symptomatic carotid plaque using S-nitrosoglutathione. Circulation 2002;105:1480–4.Google Scholar

Colagiovanni, DB, Borkhataria, D, Looker, D, et al. Preclinical 28-day inhalation toxicity assessment of s-nitrosoglutathione in beagle dogs and Wistar rats. Int J Toxicol 2011;30:466–77.Google Scholar

Facchinetti, F, Neri, I, Piccinini, F, et al. Effect of L-arginine load on platelet aggregation: a comparison between normotensive and preeclamptic pregnant women. Acta Obstet Gynecol Scand 1999;78:515–9.Google Scholar

Vadillo-Ortega, F, Perichart-Perera, O, Espino, S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011;342:d2901.Google Scholar

Neri, I, Monari, F, Sgarbi, L, Berardi, A, Masellis, G, Facchinetti, F. L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J Matern Fetal Neonatal Med 2010;23:1456–60.Google Scholar

Samangaya, RA, Mires, G, Shennan, A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:369–82.Google Scholar

Ramesar, SV, Mackraj, I, Gathiram, P, Moodley, J. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2011;157:136–40.Google Scholar

Herraiz, S, Pellicer, B, Serra, V, et al. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG 2012;119:1394–402.Google Scholar

Stanley, JL, Andersson, IJ, Poudel, R, et al. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension 2012;59:1021–8.Google Scholar

Nassar, AH, Masrouha, KZ, Itani, H, Nader, KA, Usta, IM. Effects of sildenafil in Nω-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model. Amer J Perinatol 2012;29:429–34.Google Scholar

Sharp, A, Cornforth, C, Jackson, R, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health 2018;2:93–102.Google Scholar

Colagiovanni, DB, Drolet, DW, Langlois-Forget, E, Piché, M-P, Looker, D, Rosenthal, GJ. A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma. Regul Toxicol Pharmacol 2012;62:115–24.Google Scholar

Hibbard, JU, Shroff, SG, Cunningham, FG. Cardiovascular alterations in normal and preeclamptic pregnancies. In Taylor, RN, Roberts, JM, Cunningham, FG (eds): Chesley’s Hypertensive Disorders in Pregnancy, 4th edn. Amsterdam, Academic Press, 2014.Google Scholar

Clapp, JF, Capeless, E. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol 1997;80(11):1469–73.Google Scholar

Duvekot, JJ, Cheriex, EC, Pieters, FA, et al: Early pregnancy changes in hemodynamics and volume homeostatis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 1993;169:1382.Google Scholar

MacGillivray, I, Rose, GA, Rowe, B. Blood pressure survey in pregnancy. Clin Sci. 1969;37(2):395–407.Google Scholar

World Health Organization International Collaborative Study of Hypertensive Disorders in Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol. 1988;158: 80–3.Google Scholar

Sibai, B, Dekker, G, Kupferminc, M. Pre-eclampsia. Lancet 2005;365:785–99.Google Scholar

Cedergren, M. Effects of gestational weight gain and body mass index on obstetric outcome in Sweden. Int. J. Gynaecol Obstet 2006; 93:269–74.Google Scholar

Redman, CW, Sargent, IL. Latest advances in understanding preeclampsia. Science 2005;308:1592–4.Google Scholar

Khong, TY, De Wolf, F, Robertson, WB, Brosens, I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049–59.Google Scholar

Widmer, M, Villar, J, Benigni, A, Conde-Agudelo, A, Karumanchi, SA, Lindheimer, M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007 Jan;109(1):168–80.Google Scholar

Meher, S, Duley, L. Prevention of Pre-eclampsia Cochrane Review Authors. Interventions for preventing preeclampsia and its consequences: generic protocol. Cochrane Database of Systematic Reviews 2005; 2. [doi: 10.1002/ 14651858.CD005301]Google Scholar

Redman, CW, Sacks, GP, Sargent, IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180: 499–506.Google Scholar

Everett, TR, Mahendru, AA, McEniery, CM, Wilkinson, IB, Lees, CC. Raised uterine artery impedance is associated with increased maternal arterial stiffness in the late second trimester. Placenta. 2012;33(7):572–7. doi: 10.1016/j.placenta.2012.04.001. Epub 2012 Apr 24.Google Scholar

Ghidini, A, Locatelli, A. Monitoring of fetal well-being: role of uterine artery Doppler. Semin Perinatol. 2008;32(4):258–62. doi: 10.1053/j.semperi.2008.04.019.Google Scholar

Napolitano, R, Thilaganathan, B. Mean, lowest, and highest pulsatility index of the uterine artery and adverse pregnancy outcome in twin pregnancies. Am J Obstet Gynecol. 2012;206(6):e8–9; author reply e9. doi: 10.1016/j.ajog.2012.02.030. Epub 2012 Mar 6.Google Scholar

Groom, KM, North, RA, Stone, PR, et al. SCOPE Consortium. Patterns of change in uterine artery Doppler studies between 20 and 24 weeks of gestation and pregnancy outcomes. Obstet Gynecol. 2009;113(2, Pt 1):332–8. doi: 10.1097/AOG.0b013e318195b223.Google Scholar

Myatt, L, Clifton, RG, Roberts, JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012;119(6):1234–42. doi: 10.1097/AOG.0b013e3182571669.Google Scholar

George, EM, Granger, JP. Mechanisms and potential therapies for preeclampsia. Curr Hypertens Rep 2011;13:269–75.Google Scholar

Goulopoulou, S, Davidge, ST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. Trends Mol Med 2015;21:88–97.Google Scholar

Moncada, S, Higgs, A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002–12.Google Scholar

Jeremy, JY, Rowe, D, Emsley, AM, Newby, AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43:580–94.Google Scholar

Gaboury, JP, Niu, XF, Kubes, P. Nitric oxide inhibits numerous features of mast cell-induced inflammation. Circulation 1996; 93:318–26.Google Scholar

Krause, BJ, Hanson, MA, Casanello, P. Role of nitric oxide in placental vascular development and function. Placenta. 2011; 32(11): 797–805. doi: 10.1016/j.placenta.2011.06.025.Google Scholar

Kulandavelu, S, Whiteley, KJ, Bainbridge, SA, et al. Endothelial NO synthase augments fetoplacental blood flow, placental vascularization, and fetal growth in mice. Hypertension. 2013;61(1):259–66. doi: 10.1161/HYPERTENSIONAHA.112.201996. Epub 2012 Nov 12.Google Scholar

Learmont, JG, Poston, L. Nitric oxide is involved in flow-induced dilation of isolated human small fetoplacental arteries. Am J Obstet Gynecol 1996; 174: 1056–60.Google Scholar

Hubel, CA, Kagan, VE, Kisin, ER, McLaughlin, MK, Roberts, JM. Increased ascorbate radical formation and ascorbate depletion in plasma from women with preeclampsia: implications for oxidative stress. Free Radic Biol Med 1997;23:597–609.Google Scholar

Lowe, DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000;4(4):441–58.Google Scholar

Davidge, ST, Stranko, CP, Roberts, JM. Urine but not plasma nitric oxide metabolites are decreased in women with preeclampsia. Am J Obstet Gynecol 1996;174(3):1008–13.Google Scholar

Seligman, SP, Buyon, JP, Clancy, RM, Young, BK, Abramson, SB. The role of nitric oxide in the pathogenesis of preeclampsia. American Journal of Obstetrics and Gynecology 1994;171:944–8.Google Scholar

Delacretaz, E, DeQuay, N, Waeber, B, et al. Differential nitric oxide synthase activity in human platelets during normal pregnancy and preeclampsia. Clin Sci 1995;88:607–10.Google Scholar

Neri, I, Piccinini, F, Marietta, M, Facchinetti, F, Volpe, A. Platelet responsiveness to L-arginine in hypertensive disorders of pregnancy. Hypertension in Pregnancy 2000;19(3):323–30.Google Scholar

Fickling, SA, Williams, D, Vallance, P, Nussey, SS, Whitley, GStJ. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and preeclampsia. Lancet 1993;342:242–3.Google Scholar

Noris, M, Todeschini, M, Cassis, P, et al. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004;43(3):614–22.Google Scholar

Morris, NH, Sooranna, SR, Learmont, JG, et al. Nitric oxide synthase activities in placental tissue from normotensive, preeclamptic, and growth retarded fetuses. Br J Obstet Gynaecol 1995;102:711–4.Google Scholar

Wu, G, Meininger, CJ. Arginine nutrition and cardiovascular function. J Nutr 2000;130(11):2626–9Google Scholar

Vadillo-Ortega, F, Perichart-Perera, O, Espino, S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: Randomised controlled trial. BMJ 2011;342:d2901Google Scholar

Rumbold, A, Duley, L, Crowther, CA, Haslam, RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2008;1. CD004227. doi: 10.1002/14651858.CD004227.pub3.Google Scholar

Meher, S, Duley, L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;18(2):CD006490.Google Scholar

Powers, R, Weissgerber, TL, McGonigal, S, et al. [7-OR]: L-citrulline administration increases the arginine/ ADMA ratio, decreases blood pressure and improves vascular function in obese pregnant women. Pregnancy Hypertens 2015;5(1):4Google Scholar

Molelekwa, V, Akhter, P, McKenna, P, et al. Eisenmenger’s syndrome in a 27 week pregnancy-management with bosentan and sildenafil. Ir Med J 2005;98(3):87–8Google Scholar

Lacassie, HJ, Germain, AM, Valdes, G, et al. Management of eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004;103(5, Pt 2):1118–20.Google Scholar

Wareing, M, Myers, JE, O’Hara, M, Baker, PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005;90:2550–5.Google Scholar

Maharaj, CH, O’Toole, D, Lynch, T, et al. Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. Reprod Biol Endocrinol 2009;7:34Google Scholar

Malinova, M. Sildenafil – for treatment of preeclampsia and intrauterine growth restriction. Akush Ginekol (Sofiia). 2014;53(1):40–3.Google Scholar

Von Dadelszen, P, Dwinnell, S, Magee, LA, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011;118(5):624–8.Google Scholar

Trapani, A Jr, Gonçalves, LF, Pires, MM. Transdermal nitroglycerin in patients with severe preeclampsia with placental insufficiency: Effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011;38(4):389–94.Google Scholar

Cacciatore, B, Halmesmäki, E, Kaaja, R, et al. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998;179(1):140–5.Google Scholar

Ramsay, B, De Belder, A, Campbell, S, et al. A nitric oxide donor improves uterine artery diastolic blood flow in normal early pregnancy and in women at high risk of pre-eclampsia. Eur J Clin Invest 1994;24(1):76–8.Google Scholar

Grunewald, C, Kublickas, M, Carlström, K, et al. Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia. Obstet Gynecol 1995;86(4 Pt 1):600–4.Google Scholar

Belkacemi, L, Bainbridge, SA, Dickinson, MA, Smith, GN. Glyceryl trinitrate inhibits hypoxia/reoxygenation-induced apoptosis in the syncytiotrophoblast of the human placenta: Therapeutic implications for preeclampsia. Am J Pathol 2007;170(3):909–20.Google Scholar

Lees, C, Langford, E, Brown, AS, de Belder, A, Pickles, A, Martin, JF. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstetrics & Gynecology 1996;88:14–19.Google Scholar

Thaler, I, Amit, A, Kamil, D, Itskovitz-Eldor, J. The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension. Am J Hypertens 1999;12(4 Pt 1):341–7.Google Scholar

Cetin, A, Yurtcu, N, Guvenal, T, Imir, AG, Duran, B, Cetin, M. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hypertens Pregnancy 2004; 23: 37–46.Google Scholar

Lees, C, Valensise, H, Black, R, et al. The efficacy and fetal–maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of preeclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 1998; 12:334–8.Google Scholar

Giles, W, O’Callaghan, S, Boura, A, Walters, W. Reduction in human fetal umbilical-placental vascular resistance by glyceryl trinitrate. Lancet 1992;340(8823):856.Google Scholar

Picciolo, C, Roncaglia, N, Neri, I, Pasta, F, Arreghini, A, Facchinetti, F. Nitric oxide in the prevention of pre-eclampsia. Prenat Neonatal Med 2000; 5: 212–15.Google Scholar

Chen, Z, Zhang, J, Stamler, JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002; 99: 8306–11.Google Scholar

Miller, MR, Megson, IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151: 305–21.Google Scholar

Davis, G, Brown, M. Glyceryl trinitrate patches are unsuitable in hypertensive pregnancy. Aust N Z J Obstet Gynaecol 2001;41(4):474.Google Scholar

Duvekot, JJ, Cheriex, EC, Pieters, FA, Peeters, LH. Severely impaired fetal growth is preceded by maternal hemodynamic maladaptation in very early pregnancy. Acta Obstet Gynecol Scand 1995; 74: 693–7.Google Scholar

Duvekot, JJ, Cheriex, EC, Pieters, FA, Menheere, PP, Schouten, HJ, Peeters, LH. Maternal volume homeostasis in early pregnancy in relation to fetal growth restriction. Obstet Gynecol 1995;85:361–7.Google Scholar

Valensise, H, Vasapollo, B, Novelli, GP, et al. Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. Ultrasound Obstet Gynecol 2008;31:55–64.Google Scholar

Valensise, H, Novelli, GP, Vasapollo, B, et al. Maternal cardiac systolic and diastolic function: relationship with uteroplacental resistances. A Doppler and echocardiographic longitudinal study. Ultrasound Obstet Gynecol 2000; 15: 487–97.Google Scholar

Curran-Everett, D, Morris, KG Jr, Moore, LG. Regional circulatory contributions to increased systemic vascular conductance of pregnancy. Am J Physiol 1991;261:H1842–H1847.Google Scholar

Valensise, H, Vasapollo, B, Novelli, GP, Altomare, F, Arduini, D. Nitric oxide donors and fluid therapy increase fetal growth in gestational hypertension. 15th World Congress on Ultrasound in Obstetrics and Gynecology Poster abstracts.Google Scholar

Ariyaratnam, P, Loubani, M, Morice, AH. Hydrogen sulphide vasodilates human pulmonary arteries: A possible role in pulmonary hypertension? Microvasc Res 2013;90:135–7.Google Scholar

Zhao, W, Zhang, J, Lu, Y, Wang, R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 2001;20(21):6008–16.Google Scholar

Cindrova-Davies, T. Reduced cystathionine glyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: Hydrogen sulfide as a placental vasodilator. Am J Pathol 2013;182(4):1448.Google Scholar

Cai, W, Wang, M, Moore, PK, et al. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 2008;76(1):29–40.Google Scholar

Holwerda, KM. Hydrogen sulfide producing enzymes in pregnancy and preeclampsia. Placenta 2012;33(6):518–21.Google Scholar

Holwerda, KM, Burke, SD, Faas, MM, et al. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol 2014;25(4):717–25.Google Scholar

Sharma, D, Singh, A, Trivedi, SS, Bhattacharjee, J. Role of endothelin and inflammatory cytokines in pre-eclampsia – a pilot North Indian study. Am J Reprod Immunol 2011;65(4):428–32.Google Scholar

Taylor, RN, Varma, M, Teng, NN, Roberts, JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990;71(6):1675–7.Google Scholar

Dekker, GA, Kraayenbrink, AA, Zeeman, GG, van Kamp, GJ. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1991;40(3):215–20.Google Scholar

Clark, BA, Halvorson, L, Sachs, B, Epstein, FH. Plasma endothelin levels in preeclampsia: Elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol. 1992;166(3):962–8.Google Scholar

George, EM, Palei, AC, Granger, JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: Therapeutic implications. Curr Opin Nephrol Hypertens 2012;21(2):157–62.Google Scholar

Olson, GL, Saade, GR, Buhimschi, I, et al. The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia. Am J Obstet Gynecol 1999;181(3):638–41.Google Scholar

Alexander, BT, Rinewalt, AN, Cockrell, KL, et al. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001;37(2 Pt 2):485–9.Google Scholar